A Phase 3 interventional study of TransCon hGH and daily hGH in Growth Hormone Deficiency, Endocrine System Diseases and Hormones, sponsored by Visen Pharmaceuticals (Shanghai) Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-03-30.
Sponsored by Visen Pharmaceuticals (Shanghai) Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Dwarfism, Pituitary with a site in China — 4 open to participants now, 4 under way, 2 of them phase 3. Dwarfism, Pituitary · China.
Among the 15 studies in Dwarfism, Pituitary with a site in China, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2019, is one of 3 in phase 3, and was the 8th registered.
252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.
Browse Dwarfism, Pituitary studies →4 of the 15 studies in Dwarfism, Pituitary with a site in China are open now. Recruiting first, the newest first:
Xiamen Amoytop Biotech Co., Ltd. · Sites in China
Ages 18–80 · Men only
Kexing Biopharm Co., Ltd. · Sites in China
Ages 3–11
Changchun GeneScience Pharmaceutical Co., Ltd. · Sites in China
Ages 18–70 · Healthy volunteers
Shenzhen Kexing Pharmaceutical Co., Ltd. · Sites in China
Ages 3–11
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 3 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 5 · Phase 4 5
First in 2007; this study’s year is marked. 1 started in 2019.
This study's planned enrollment of 150 is above the median of 60 across 169 interventional studies indexed under Dwarfism, Pituitary.
Median enrollment 306 across the 14 interventional studies, 500 across the 1 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 6 most frequent:
Visen Pharmaceuticals (Shanghai) Co., Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Visen Pharmaceuticals (Shanghai) Co., Ltd. has 1 study filed under Dwarfism, Pituitary — fewer than ten, so there is no comparison to draw.
1 of the studies in Dwarfism, Pituitary with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07016802Changchun GeneScience Pharmaceutical Co., Ltd.A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD) | 2026-11-25 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Dwarfism, Pituitary with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is conducted in China only. The purpose is to demonstrate the efficacy and safety of once weekly dosing of TransCon hGH, a long-acting growth hormone product, compare to once-daily dosing of human growth hormone (hGH) after 52 weeks of treatment in prepubertal children with growth hormone deficiency (GHD).
Not Provided
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TransCon hGH will be self-administered or injected by parents once weekly. The dose will be adjusted based on subject's weight. The treatment will continue 52 weeks.
Drug: TransCon hGH
Daily hGH will be self-administered or injected by parents once daily. The dose will be adjusted based on subject's weight. The treatment will continue 52 weeks.
Drug: daily hGH
Once weekly subcutaneous injection
Also known as: ACP-011
Once daily subcutaneous injection
Also known as: somatropin (rDNA orgin) for injection
Annualized height velocity(AHV) at Week 52
Annualized height velocity at Week 52 for weekly TransCon hGH treatment and the daily hGH treatment groups
Time frame: 52 Weeks
AHV and the change from baseline over 52 weeks at each visit
AHV and the change from baseline for the TransCon hGH and the daily hGH treatment group over 52 weeks at each visit
Time frame: 52 Weeks
Height SDS and the change from baseline over 52 weeks
Height SDS and the change from baseline for the TransCon hGH and the daily hGH treatment group over 52 weeks
Time frame: 52 weeks
Serum IGF-1 and IGFBP-3 levels, and IGF-1 SDS, IGFBP-3 SDS, and the change from baseline over 52 weeks at each visit
Serum IGF-1 and IGFBP-3 levels, and IGF-1 SDS, IGFBP-3 SDS, and the change from baseline for the TransCon hGH and the daily hGH treatment group over 52 weeks at each visit
Time frame: 52 weeks
The percentage of participants achieving IGF-1 SDS 0 to +2.0
The normalization of IGF-1 SDS (percentage of participants achieving IGF-1 SDS 0 to +2.0 over 52 weeks for the TransCon hGH and the daily hGH treatment group
Time frame: 52 weeks
Incidence of Treatment-Emergent Adverse Events
Time frame: 52 weeks
The plasma concentration
pharmacokinetics measure of hGH over 52 weeks in TransCon hGH group
Time frame: 52 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2019 (actual). Primary completion is estimated for Apr 2022, 28 months after the start.
Of 19 phase 3 interventional studies under Dwarfism, Pituitary, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's planned 28 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lonapegsomatropin
Visen Pharmaceuticals (Shanghai) Co., Ltd.